Vistagen Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell VTGN and other ETFs, options, and stocks.About VTGN
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia).
CEOShawn K. Singh
CEOShawn K. Singh
Employees57
Employees57
HeadquartersSouth San Francisco, California
HeadquartersSouth San Francisco, California
Founded1998
Founded1998
Employees57
Employees57
VTGN Key Statistics
Market cap27.80M
Market cap27.80M
Price-Earnings ratio-0.44
Price-Earnings ratio-0.44
Dividend yield—
Dividend yield—
Average volume1.76M
Average volume1.76M
High today—
High today—
Low today—
Low today—
Open price$0.672
Open price$0.672
Volume0.00
Volume0.00
52 Week high$5.14
52 Week high$5.14
52 Week low$0.6311
52 Week low$0.6311
Stock Snapshot
As of today, Vistagen Therapeutics(VTGN) shares are valued at $0.70. The company's market cap stands at 27.8M, with a P/E ratio of -0.44.
On 2026-01-15, Vistagen Therapeutics(VTGN) shares started trading at $0.67, with intraday highs of — and lows of —.
Trading volume for Vistagen Therapeutics(VTGN) stock has reached 0, versus its average volume of 1.76M.
Over the past 52 weeks, Vistagen Therapeutics(VTGN) stock has traded between a high of $5.14 and a low of $0.63.
Over the past 52 weeks, Vistagen Therapeutics(VTGN) stock has traded between a high of $5.14 and a low of $0.63.
People also own
Based on the portfolios of people who own VTGN. This list is generated using Robinhood data, and it’s not a recommendation.